Article: Developing Plasmodium falciparum malaria vaccines for populations living in areas with stable parasite transmission Journal: International Journal of Biotechnology (IJBT) 2007 Vol.9 No.3/4 pp.292 - 300 Abstract: Individuals living in areas with stable transmission of Plasmodium falciparum parasites develop substantial protective immunity to the disease during childhood. Because of naturally acquired immunity, which appears mainly to target parasite-encoded Variable Surface Antigens (VSA) on the Infected Erythrocytes (IE), severe and life-threatening disease among adults in such areas is rare. However, low-grade asymptomatic parasitaemia continues to be present in a large proportion of people. So far, experimental P. falciparum malaria vaccination employing non-VSA antigens have resulted in variable degrees of protection, including sterile protection, but the duration of the protection afforded is short-lived, probably due to insufficient boosting. Based on these findings, our approach to vaccine development is to accelerate naturally acquired VSA-specific immunity. The ambition is to develop vaccines that will protect against mortality and severe morbidity, but which allow persistence of low-grade, asymptomatic infection. Hopefully, this approach will ensure regular boosting of immunity that appears necessary for the long-lasting protection required of vaccines to be deployed in malaria-endemic areas. Inderscience Publishers - linking academia, business and industry through research

Title: Developing Plasmodium falciparum malaria vaccines for populations living in areas with stable parasite transmission

Authors: Lars Hviid, Thor G. Theander

Addresses: Department of Infectious Diseases M7641, Rigshospitalet, Blegdamsvej 9, Copenhagen O 2100, Denmark. ' Institute for Medical Microbiology and Immunology, University of Copenhagen, Blegdamsvej 3, Copenhagen N 2200, Denmark

Abstract: Individuals living in areas with stable transmission of Plasmodium falciparum parasites develop substantial protective immunity to the disease during childhood. Because of naturally acquired immunity, which appears mainly to target parasite-encoded Variable Surface Antigens (VSA) on the Infected Erythrocytes (IE), severe and life-threatening disease among adults in such areas is rare. However, low-grade asymptomatic parasitaemia continues to be present in a large proportion of people. So far, experimental P. falciparum malaria vaccination employing non-VSA antigens have resulted in variable degrees of protection, including sterile protection, but the duration of the protection afforded is short-lived, probably due to insufficient boosting. Based on these findings, our approach to vaccine development is to accelerate naturally acquired VSA-specific immunity. The ambition is to develop vaccines that will protect against mortality and severe morbidity, but which allow persistence of low-grade, asymptomatic infection. Hopefully, this approach will ensure regular boosting of immunity that appears necessary for the long-lasting protection required of vaccines to be deployed in malaria-endemic areas.

Keywords: malaria vaccines; Plasmodium falciparum; endemic countries; children; pregnant women; asexual blood stages; stable parasite transmission; protective immunity; asymptomatic parasitaemia; variable surface antigens; VSA.

DOI: 10.1504/IJBT.2007.014249

International Journal of Biotechnology, 2007 Vol.9 No.3/4, pp.292 - 300

Published online: 27 Jun 2007 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article

Title: Developing Plasmodium falciparum malaria vaccines for populations living in areas with stable parasite transmission

Keep up-to-date